Jessica Rice, APRN
Adult Health · Greenville, SCNPI 1992278394
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,563 of the $14,532 with a category attached, or 72.7%. AbbVie accounts for 81.9% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $8,580, more than ten times the $379 reported in 2021. Among adult health clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $57.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Lundbeck LLC$285
- Novartis$243
- Otsuka America Pharmaceutical, Inc.$199
- Amgen$166
- Teva Pharmaceuticals USA, Inc.$154
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$10,56373%
- Travel & lodging$630%
- Food & beverage$3,89527%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 110 | $11,900 |
| Lundbeck LLC | 17 | $285 |
| Novartis | 13 | $243 |
| Otsuka America Pharmaceutical, Inc. | 13 | $199 |
| Amgen(2 entities) | 8 | $166 |
| Teva Pharmaceuticals USA, Inc. | 7 | $154 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $153 |
| SK Life Science, Inc. | 7 | $144 |
| ANI Pharmaceuticals, Inc. | 5 | $126 |
| AstraZeneca | 5 | $92 |
| CSL Behring | 3 | $89 |
| UCB, Inc. | 4 | $82 |
| Lilly USA, LLC | 4 | $81 |
| Sunovion Pharmaceuticals Inc. | 5 | $77 |
| Upsher-smith Laboratories LLC | 4 | $70 |
| Pfizer | 3 | $59 |
| Banner Life Sciences, LLC | 3 | $58 |
| Johnson & Johnson | 3 | $58 |
| Impel Pharmaceuticals Inc. | 3 | $53 |
| Eisai Inc. | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Biogen | 2 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| GE HealthCare | 1 | $37 |
| EMD Serono, Inc. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Genentech USA, Inc. | 1 | $20 |
| Tanabe Pharma America, Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,532 in reported general payments places this provider in the 95th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 47 | $70,887 |
| Nurtec OdtRimegepant Sulfate | 22 | $43,278 |
| Aimovig AutoinjectorErenumab-Aooe | 28 | $32,319 |
| BrilintaTicagrelor | 34 | $21,402 |
| QuliptaAtogepant | 14 | $20,901 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 17 | $18,942 |
| EliquisApixaban | 11 | $9,749 |
| VascepaIcosapent Ethyl | 15 | $7,003 |
| Repatha SureclickEvolocumab | 12 | $6,464 |
| Levetiracetam | 173 | $4,377 |
| RivastigmineRivastigmine Tartrate | 49 | $2,216 |
| Lacosamide | 33 | $1,597 |
| Baclofen | 27 | $1,282 |
| Carbamazepine ErCarbamazepine | 19 | $1,239 |
| Atorvastatin Calcium | 84 | $987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $11,900 | $91,78861 claims |
| PfizerNurtec Odt, Eliquis | $59 | $53,02733 claims |
| AstraZenecaBrilinta | $92 | $21,40234 claims |
| Upsher-smith Laboratories LLCTopiramate | $70 | $19830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 adult health providers in South Carolina.
Other adult health in Greenville
- Karen RobertsonGreenville$69K
- Sheri MorrisGreenville$8K
- James McKenzieGreenville$8K
- Gary SzetoGreenville$6K
- John SharkeyGreenville$6K
- Sarah BaranskiGreenville$5K
- Brandi RuffoGreenville$4K
- Lynn CurryGreenville$4K
- Christine FranzeseTega Cay$30K
- Michelle PriceCharleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.